Phase I / II Clinical Trials

 

St. Jude Clinical Trials

ALLR18: Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma

Diseases Treated:

Relapsed or refractory precursor B-cell acute lymphoblastic leukemia and lymphoma

Eligibility:

  • B-cell acute lymphoblastic leukemia or lymphoblastic lymphoma that has:
    • Come back after treatment the first time
    • Did not respond to treatment the first time
  • Less than 22 years of age
  • Does not have HIV or hepatitis B infection
View Trial

AOST1421: Combination Drug Therapy to Treat Patients with Recurrent Osteosarcoma

Diseases Treated:

Osteosarcoma

Eligibility:

  • Younger than 30 years old
  • Original diagnosis of osteosarcoma
  • Osteosarcoma has come back in the lungs after original treatment
  • Lung tumors have been removed surgically within the last 4 weeks before enrolling in the study
View Trial

ASCIST: Donor Natural Killer Cell Infusion after Autologous CD133+ Selected Stem Cell Transplant in Treating Younger Patients with High-Risk Solid Tumors or Lymphomas

Diseases Treated:

High-risk solid tumors and lymphomas

Eligibility:

  • Has a type of high-risk cancer including
    • Neuroblastoma
    • Solid tumors
    • Lymphomas
  • 21 years of age or younger
  • Has not received a prior hematopoietic (blood cells from bone marrow) stem cell transplant within the previous three months
View Trial

BECHEM: Bendamustine, Clofarabine and Etoposide in Treating Younger Patients with Relapsed or Refractory Hematologic Malignancies

Diseases Treated:

Relapsed or refractory hematologic malignancies

Eligibility:

  • Diagnosis of Hodgkin lymphoma, non-Hodgkin lymphoma or leukemia that has come back or did not respond to treatment
  • Must be 21 years of age or younger at the time of enrollment
  • Must have adequate kidney and heart function 
View Trial

BMNIRN: Talazoparib Plus Irinotecan With or Without Temozolomide in Children with Refractory or Recurrent Solid Malignancies

Diseases Treated:

Relapsed or refractory solid tumors

Eligibility:

  • Participant has refractory or recurrent solid tumor for which there is no standard therapy.
  • Participant has had histologic verification of malignancy at original diagnosis or at the time of relapse.
  • Participant is twelve (12) months to twenty-five (25) years of age at the time of enrollment on study.
  • Participant life expectancy is at least eight (8) weeks. 
View Trial

ED0157: Phase 1 Pediatric PK/PD Study

Diseases Treated:

For patients at risk for blood clots

Eligibility:

  • Participant has a diagnosis requiring anticoagulant therapy.
  • Participant has completed their standard anticoagulant therapy.
  • Participant is not receiving active therapy for a malignant condition.
  • Participant is less than 18 years of age at the time of consent.
  • Participant and legal guardian agree to food and drug restrictions during study.
View Trial

EWS1221: Phase II Study of Ganitumab with Chemotherapy for Patients with Metastatic Ewing Sarcoma

Diseases Treated:

Ewing sarcoma

Eligibility:

  • Younger than or equal to 50 years old
  • Diagnosis of Ewing sarcoma or peripheral primitive neuroectodermal tumor (PNET) arising from bone or soft tissue and with metastatic disease involving lung, bone, bone marrow or other metastatic site
View Trial

HLHR13: Brentuximab Vedotin, Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients with Stage IIB-IVB Hodgkin Lymphoma

Diseases Treated:

High-risk Hodgkin lymphoma

Eligibility:

  • Has high-risk Hodgkin lymphoma
  • 18 years of age or younger
  • Has not received previous treatment for Hodgkin lymphoma
View Trial

HOD08: Combination Chemotherapy with or without Radiation Therapy in Treating Young Patients with Favorable-Risk Hodgkin Lymphoma

Diseases Treated:

Hodgkin lymphoma

Eligibility:

  • Diagnosis of early-stage Hodgkin lymphoma 
  • Hodgkin lymphoma that has not been previously treated
  • 21 years of age or younger
View Trial

iRET: Intravitreal Chemotherapy for Children with Retinoblastoma

Diseases Treated:

Retinoblastoma

Eligibility:

  • Age 17 or younger
  • Diagnosis of retinoblastoma that did not go away with treatment or came back after treatment
View Trial

LTE1621: Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2B Randomized Placebo-Controlled (Carvedilol) Trial

Diseases Treated:

Cancer

Eligibility:

  • Younger than 21 years old at time of cancer diagnosis
  • Weight:
    • Males: more than 55 kilograms (about 121 pounds)
    • Females: more than 50 kilograms (about 110 pounds)
  • Lifetime cumulative anthracycline dose: ≥ 300 mg/m2 DOXOrubicin equivalent without the protection of dexrazoxane (Zinecard) therapy
  • Completed cancer treatment at least 2 years prior to study enrollment
View Trial

MEKPEM: A Phase I/II Study of Pembrolizumab (MK-3475) in Children with Advanced Melanoma or a PD-L1 Positive Advanced Relapsed or Refractory Solid Tumor or Lymphoma

Diseases Treated:

Advanced melanoma or PD-L1 positive advanced relapsed or refractory solid tumor or lymphoma

Eligibility:

  • Participant has advanced melanoma or PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma
  • Participant of child bearing potential has a negative pregnancy test 72 hours prior to medication administration
  • Participant has appropriate liver and kidney function
View Trial

MITREL: A Phase II Study of Microtransplantation in Patients with Refractory or Relapsed Hematologic Malignancies

Diseases Treated:

Refractory or relapsed acute myeloid leukemia (AML), myelodysplastic syndrome (MDS)

Eligibility:

  • Patient should be is less than or equal to twenty-one years of age.
  • Patient has a diagnosis of AML or MDS that has relapsed or is refractory to chemotherapy or has relapsed after HSCT.
  • Patient has an available HPC-A donor.
View Trial

NB2012: Therapy for Children with Advanced Stage High-Risk Neuroblastoma

Diseases Treated:

Neuroblastoma

Eligibility:

  • Participant is < 19 years of age at the time of study enrollment.
  • Participant has newly diagnosed, advanced stage, high-risk neuroblastoma.
  • Participant has histologic proof of neuroblastoma or positive bone marrow for tumor cells with increased urine catecholamine.
  • Participant has adequate renal and hepatic function.
View Trial

NHL16: Study for Newly Diagnosed Patients with Acute Lymphoblastic Lymphoma

Diseases Treated:

Acute lymphoblastic leukemia

Eligibility:

  • 21 years of age or younger
  • Newly diagnosed lymphoblastic lymphoma
  • Has received one week or less prior treatment for lymphoblastic lymphoma
View Trial

PANAML: Panobinostat, Fludarabine and Cytarabine in Patients with AML or MDS

Diseases Treated:

Acute myeloid leukemia (AML), myelodysplastic syndrome (MDS)

Eligibility:

  • Diagnosis of AML or MDS that has come back or did not respond to chemotherapy
  • 21 years of age or younger at time of enrollment
  • Able to swallow capsules
  • Recovered from side effects of previous cancer therapy
View Trial

PMVOC: Pain Management of Vaso-Occlusive Crisis in Children and Young Adults with Sickle Cell Disease

Diseases Treated:

Sickle cell disease

Eligibility:

This is a non-therapeutic clinical trial that is only open to St. Jude patients.

View Trial

RADIANT: Donor Hematopoietic Stem Cell Transplant in Treating Young Patients with Relapsed or Refractory Solid Tumors or Lymphomas

Diseases Treated:

Relapsed or refractory solid tumors or lymphomas

Eligibility:

  • Between the ages of 2 and 21 years
  • Solid tumor or lymphoma as primary cancer
  • Cancer that has come back or did not respond to previous chemotherapy
  • No heart, kidney or liver problems
View Trial

REF2HCT: Haploidentical Bone Marrow Transplant for Leukemia and Lymphoma

Diseases Treated:

Eligibility:

  • 21 years old and younger
  • Diagnosed with one of the following that has come back or did not improve after bone marrow transplant
    • Acute lymphoblastic leukemia (ALL)
    • Acute myeloid leukemia
    • Myeloid sarcoma
    • Chronic myeloid leukemia (CML)
    • Juvenile myelomonocytic leukemia (JMML)
    • Myelodysplastic syndrome (MDS)
    • Non-Hodgkin lymphoma (NHL)
  • Has a family member who is a suitable stem cell donor
View Trial

RELHEM2: Crenolanib and Sorafenib Tosylate in Treating Patients with Refractory or Relapsed Hematologic Malignancies

Diseases Treated:

Refractory or relapsed hematologic malignancies (leukemia)

Eligibility:

  • Between the ages of 1 and 25 years
  • FLT3-mutated AML that has returned or did not respond to previous chemotherapy
  • No history of HIV infection, hepatitis B, or hepatitis C
View Trial

RELMLL: A Phase II Study of Bortezomib and Vorinostat in Patients with Refractory or Relapsed MLL Rearranged Hematologic Malignancies

Diseases Treated:

Relapsed or refractory leukemia / lymphoma

Eligibility:

This clinical trial has both inclusion and exclusion criteria. See Eligibility Requirements in the full trial for specifics.

View Trial

RERTEP: Surgery and Second-Course Radiation Therapy in Treating Younger Patients With Recurrent Ependymoma

Diseases Treated:

Recurrent ependymoma

Eligibility:

  • Progressive intracranial ependymoma after prior focal irradiation
  • At least 1 year old and younger than 21 years old
  • Adequate performance status (ECOG less than 3)
  • Does not require mechanical ventilation
  • Interval from start of initial radiation therapy to enrollment greater than 9 months
View Trial

RT2CR: Limited Surgery and Proton Beam Radiation Therapy in Treating Younger Patients with Brain Tumors

Diseases Treated:

Craniopharyngioma

Eligibility:

  • 21 years of age or younger
  • Diagnosis of craniopharyngioma 
  • Has not been previously treated with radiation therapy
View Trial

RT3CR: Proton Therapy for Pediatric Craniopharyngioma

Diseases Treated:

Craniopharyngioma

Eligibility:

  • 21 years old or younger
  • Diagnosis of craniopharyngioma
View Trial

SELHEM: Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome

Diseases Treated:

Relapsed or refractory leukemia or hematologic malignancies

Eligibility:

  • Up to 21 years of age
  • Acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS) or mixed phenotype acute leukemia (MPAL) that has come back or did not respond to previous treatment
  • No history of HIV infection
View Trial

SENDAI: A Phase I Study of Unmodified Live Intranasal Sendai Virus Vaccine in Children and Toddlers: Assessment of Safety and Immunogenicity

Eligibility:

  • Child is greater than or equal to twelve (12) months and less than twenty-four (24) months.
  • Child has adequate blood, liver and kidney function.
  • Child has no history of lung disease, asthma, and hospitalization for respiratory illness, immunodeficiency, sickle cell disease, or any other serious underlying condition.
View Trial

SJATRT: Phase II Study of Alisertib Therapy for Rhabdoid Tumors

Diseases Treated:

Brain Tumor : Recurrent, progressive, or newly diagnosed atypical teratoid rhabdoid brain tumors (ATRT)
Solid Tumor : Progressive extra-CNS malignant rhabdoid solid tumors (MRT)

Eligibility:

  • Has one of these types of tumors:
    • Newly diagnosed atypical teratoid rhabdoid tumors (ATRTs) or synchronous extraneural ATRTs
    • ATRTs or malignant rhabdoid tumors (MRTs) that have come back after previous treatment (recurrent disease)
    • ATRTs or MRTs that are growing after previous treatment (progressive disease)
  • 21 years of age or younger
View Trial

SJHG12: Crizotinib and Dasatinib in Treating Younger Patients with Recurrent or Progressive Diffuse Intrinsic Pontine Glioma or High-Grade Glioma

Diseases Treated:

Progressive or recurrent pontine glioma or high-grade glioma

Eligibility:

  • Between 2 and 21 years of age
  • Diagnosis of diffuse intrinsic pontine glioma (DIPG) or high-grade glioma
View Trial

SJMB12: A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma/PNET

Diseases Treated:

Medulloblastoma (includes all variants of medulloblastoma and posterior fossa PNET)

Eligibility:

  • Diagnosis of newly medulloblastoma
  • Must be least 3 but not more than 22 years of age
  • Has not received previous treatment with radiation therapy or chemotherapy
  • Must start treatment within 36 days of surgery to remove the tumor
View Trial

SJRET6: Combination Chemotherapy in Treating Patients with Newly Diagnosed, Previously Untreated Intraocular Retinoblastoma

Diseases Treated:

Retinoblastoma

Eligibility:

  • Newly diagnosed retinoblastoma that has not spread beyond the eye
  • Has not received previous treatment with chemotherapy or radiation therapy
  • Patients who have been diagnosed with retinoblastoma in one eye who did not receive chemotherapy, but then developed retinoblastoma in the opposite eye
View Trial

SJYC07: Risk-Adapted Therapy in Treating Young Children with Brain Tumors

Diseases Treated:

ATRT, PNET, medulloblastoma and other embryonal brain tumors, high-grade glioma, choroid plexus carcinoma or ependymoma

Eligibility:

  • Newly diagnosed brain tumor or tumor of the central nervous system and less than 3 years of age
  • Children between 3 and 5 years old with medulloblastoma  that has not spread  into the fluid that surrounds the brain and spinal cord can also be treated on this trial
  • No prior radiation therapy or chemotherapy
View Trial

TINI: Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL)

Diseases Treated:

Acute lymphoblastic leukemia (ALL)

Eligibility:

  • Newly diagnosed ALL
  • 1 year of age or younger at the time of diagnosis
  • Has not had any — or has had limited — prior therapy
  • Does not have mature B-cell ALL, acute myeloid leukemia (AML) or Down syndrome
View Trial

Collaborative Clinical Trials

ADV1212: Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

Diseases Treated:

Relapsed or refractory solid tumors or anaplastic large cell lymphoma

Eligibility:

  • Participant is > than 12 month and < 21 years of age at the time of enrollment.
  • Participant has histologic verification at original diagnosis or relapse or relapse of relapsed or refractory solid tumor or anaplastic large cell lymphoma (ALCL).
  • Participant does not have primary or metastatic CNS tumor.
  • Participant has not received prior therapy with crizotinib.
View Trial

ADV1217: WEE1 Inhibitor MK-1775 and Local Radiation Therapy in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas

Diseases Treated:

Newly diagnosed Diffuse Intrinsic Pontine Glioma (DIPG)

Eligibility:

  • Participant is > 36 month and < 21 years of age at the time of study enrollment.
  • Participant has newly diagnosed DIPG.
  • Participant has a brainstem tumor that was biopsied and proven to be one of the following: anaplastic astrocytoma, glioblastoma, gliosarcoma, or anaplastic mixed glioma.
  • Participant has not received any prior chemotherapy, radiation therapy, immunotherapy or bone marrow transplant for the treatment of DIPG. Prior dexamethasone and/or surgery are allowed.
View Trial

ADV1312: WEE1 Inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Diseases Treated:

Relapsed or refractory solid tumors

Eligibility:

  • Participant is >12 months and < 21 years of age at the time of study entry.
  • Participant has had histologic verification of malignancy at original diagnosis or relapse.
  • Participant has serum tumor markers including alpha-fetoprotein or beta-HCG.
  • Participant has a relapsed or refractory solid tumor.
View Trial

ADV1414: Phase I Study of Selinexor to Treat Patients with Recurrent and Refractory Pediatric Solid Tumors

Diseases Treated:

Solid Tumors

Eligibility:

  • Diagnosis of solid tumor that is resistant to other anticancer therapy or has come back after therapy. Includes lymphoma and central nervous system (CNS) tumors that may or may not require surgery.
  • Fully recovered from the acute toxic effects of all prior anticancer therapy
  • At least 1 but not more than 21 years of age
  • Able to swallow tablets whole
View Trial

BRF116: A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects

Diseases Treated:

Solid tumors, giomas, hystiocytosis

Eligibility:

  • Participant is greater or equal to 12 months and less than 18 years at the time of signing the informed consent form.
  • Participant has BRAF V600 mutation positive tumor as confirmed in a CLIA-approved laboratory or equivalent
  • Participant has recurrent disease, refractory disease, or progressive disease after having received at least one standard therapy for their disease, OR participant has metastatic (or surgically unresectable) melanoma, and is being enrolled for first-line treatment. Melanoma participants with CNS involvement may be enrolled.
View Trial

CCL0922: Modafinil in Treating Children With Memory and Attention Problems Caused by Cancer Treatment for a Brain Tumor

Diseases Treated:

Brain Tumor : Previously treated brain tumors

Eligibility:

  • Age is > 6 years and < 17 years & 10 months at the time of study entry.
  • Off treatment and progression–free for at least 12 months and less than and equal to 14 years.
  • Diagnosis of a primary brain tumor treated with at least one of the following :
    • Neurosurgical resection of the brain tumor;
    • Cranial irradiation;
    • Any chemotherapy to treat the brain tumor
View Trial

CNS1123: Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors

Diseases Treated:

Newly diagnosed localize primary NGGCT or newly diagnosed localized germinoma

Eligibility:

  • Participant is > 3 years and < 21 years at the time of enrollment.
  • Participant has newly diagnosed localized primary NGGCT or newly diagnosed localized germinoma (has not spread to other parts of the brain or spine).
  • Participant must have adequate bone marrow function.
  • Participant must have normal renal and liver function for age.
  • NO prior therapy except surgery and/or steroids.
View Trial

CSqHPV: Vaccine Therapy in Preventing Human Papillomavirus Infection in Younger Cancer Survivors

Diseases Treated:

Human papillomavirus

Eligibility:

This is a non-therapeutic clinical trial that is only open to St. Jude patients.

Questionnaire phase

  • Cancer survivor (9 to 26 years of age at study participation)
  • English or Spanish-speaking

Vaccine Phase

  • Survey response indicated no prior history of HPV vaccination
  • Agrees to return to participating institution for 3 HPV vaccine injections
  • Allergy to any component of the HPV vaccine including yeast and aluminum will not be eligible for the study
View Trial

ELVIS: Two Part Study to Study Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir (EVG) Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Subjects

Diseases Treated:

HIV Infection

Eligibility:

  • Participant does not have life expectancy of less than 1 year.
  • Participant does not have history of significant drug sensitivity or drug allergy.
  • Participant is not participating in any other clinical trial without prior approval from sponsor while participating in this trial.
  • Participant does not have an ongoing serious infection requiring systemic antibiotic therapy at the time of screening.
View Trial

EZH102: Tazemetostat in Children and Young Adults with Synovial Sarcoma or INI1-Negative Tumors

Diseases Treated:

Eligibility:

  • Between 6 months and 21 years old
  • Relapsed or refractory rhabdoid tumors, INI1-negative tumors or synovial sarcoma
View Trial

HODLP: First International Inter-Group Study for Nodular Lymphocyte Predominant Hodgkin Lymphoma in Children and Adolescents

Diseases Treated:

Lymphocyte predominant Hodgkin lymphoma 

Eligibility:

  • Diagnosis of early-stage lymphocyte-predominant Hodgkin lymphoma (LPHL)
  • LPHL that has not been previously treated with chemotherapy or radiation therapy
  • 18 years of age or younger

 

View Trial

LDKALK: Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)

Diseases Treated:

Refractory or progressive malignancies

Eligibility:

  • Age > 12 months and < 18 years.
  • Participant has been diagnosed with a locally advanced or metastatic malignancy that has progressed despite standard therapy, or which no effective standard therapy exists.
  • Specimen is being submitted for molecular pre-screening to test for genetic alteration of ALK and the tumor must carry a genetic alteration of the ALK gene.
  • Participant has adequate liver, kidney, cardiac, and bone marrow function.
View Trial

LDTAM: Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors

Diseases Treated:

For survivors of Hodgkin lymphoma

Eligibility:

  • Females, 25 years of age or older.
  • Participant does not plan to become pregnant in the next 2 years and is not currently breast feeding.
View Trial

LOXO-TRK: Testing LOXO-101 in Children with Advanced Solid Tumors or Brain Tumors

Diseases Treated:

Solid Tumors, Central Nervous System Tumors

Eligibility:

  • 1 to 21 years of age with locally advanced or metastatic solid tumor or primary CNS tumor that has progressed or was nonresponsive to therapy and for which there is no standard or available curative therapy, OR
  • ≥ 1 month old with diagnosis of infantile/congenital fibrosarcoma or congenital mesoblastic nephroma with documented NTRK fusion that has progressed or was nonresponsive to therapy and for which there is no standard or available curative therapy
View Trial

LTE1621: Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2B Randomized Placebo-Controlled (Carvedilol) Trial

Diseases Treated:

Cancer

Eligibility:

  • Younger than 21 years old at time of cancer diagnosis
  • Weight:
    • Males: more than 55 kilograms (about 121 pounds)
    • Females: more than 50 kilograms (about 110 pounds)
  • Lifetime cumulative anthracycline dose: ≥ 300 mg/m2 DOXOrubicin equivalent without the protection of dexrazoxane (Zinecard) therapy
  • Completed cancer treatment at least 2 years prior to study enrollment
View Trial

MEK116: Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations

Diseases Treated:

Relapsed or refractory solid tumor

Eligibility:

  • Participant is at least one month old and younger than 18 years old at the time of signing the informed consent (in Part A, participants < 2 years of age are not included).
  • Participant has a histologically confirmed solid tumor
  • Participant has a disease that is relapsed or refractory to all potentially curative standard treatment regimens, or has a disease for which there is no standard treatment regimen that is potentially curative.
View Trial

NOTCHES1: Novel Therapies in Children with Sickle Cell Disease

Diseases Treated:

Sickle cell disease

Eligibility:

  • 12 to 17 years old
  • Diagnosis of sickle cell disease
  • Able to swallow capsules

 

View Trial

P1093: Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants, Children, and Adolescents

Diseases Treated:

Human Immunodeficiency Virus

Eligibility:

  • At least 4 weeks old but younger than 18 years old
  • Confirmed HIV-1 infection
  • Current or past treatment with HIV medications (Children younger than 2 years old may be eligible even if they have not been treated with HIV medications.)
View Trial

PBTC29: Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma

Diseases Treated:

Gliomas

Eligibility:

  • Participant is ≥ 3 but ≤ 21 years of age at registration.
  • Participant has a diagnosis of low grade glioma (Grades I & II) or optic pathway gliomas with clinical and/or radiographic evidence of progression.
  • Participant received last fraction of local irradiation to the primary tumor ≥ 12 weeks prior to registration, or does not apply.
View Trial

PBTC39: Peginterferon Alfa-2b in Treating Younger Patients With Craniopharyngioma That is Recurrent or Cannot Be Removed By Surgery

Diseases Treated:

Unresectable or recurrent craniopharyngioma

Eligibility:

  • Participant has a histologically verified diagnosis of craniopharyngioma.
  • Participant has recovered from acute toxicities of all prior therapy before entering this study.
  • Participant has not received prior interferon, either systemic or into the tumor cyst.
  • Participant does not have evidence of metastatic tumor.
View Trial

PBTC42: Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors

Diseases Treated:

Retinoblastoma protein 1 (Rb1) positive recurrent, progressive, or refractory central nervous system tumors

Eligibility:

  • Participant between four (4) and twenty-one (21) years of age at time of enrollment.
  • Participant has histologically confirmed Rb1 positive recurrent, progressive, or refractory CNS tumor or DIPG.
  • Participant with a neurological deficit that is stable for at least one (1) week prior to enrollment.
  • Participant has received last dose of known myelosuppressive anticancer chemotherapy at least three (3) weeks prior to enrollment.
  • Participant has received last fraction of focal irradiation > two (2) weeks prior to enrollment.
View Trial

PBTC47: A Clinical Trial of the Drug, Panobinostat, in Children with Brain Tumors

Diseases Treated:

Diffuse Intrinsic Pontine Glioma (DIPG)

Eligibility:

  • Diagnosis of progressive diffuse intrinsic pontine glioma (DIPG) or an increase in the bi-dimensional measurement or the appearance of a new tumor lesion since diagnosis
  • At least 2 but not more than 22 years old
  • Able to swallow capsules whole
View Trial

PNOC001: Phase II Study of Everolimus for Recurrent or Progressive Low-Grade Gliomas in Children (CC #120817)

Diseases Treated:

Recurrent or progressive low grade gliomas (brain tumors)

Eligibility:

  • Participant is three (3) to twenty-one (21) years of age.
  • Patient has refractory, progressive or recurrent confirmed low-grade glioma (WHO grade I or II) that was confirmed histologically at initial diagnosis.
  • Participant received his or her last dose of myelosuppressive anticancer chemotherapy at least three (3) weeks prior to study registration, or at least six (6) weeks if nitrosourea.
  • Participant received his or her last dose of other investigational or biological agent more than seven (7) days prior to study entry.
View Trial

REFGCT: A Phase II Study of Two Drugs for Relapsed or Refractory Malignant Germ Cell Tumors

Diseases Treated:

Refractory and recurrent solid tumors

Eligibility:

  • Participant is between 1-25 years old e at the time of enrollment (Note:  eligibility up to age 50 years for other participating sites).
  • Participant has had histologic verification of an extracranial germ cell tumor that is not a pure teratoma (mature or immature), pure germinoma, or pure seminoma.
  • Participant has relapsed or refractory disease following at least two prior platinum-containing chemotherapy regimens.
  • Patients must have measurable disease, documented according to RECIST criteria, or evaluable disease with a standard tumor marker (AFP and/or HCG) greater than 10 times the upper limit of normal.
  • Other requirements for this study.
View Trial

SBRT1: Stereotactic Radiation Therapy for Pediatric Sarcomas

Diseases Treated:

Metastatic sarcomas

Eligibility:

  • Participant has histologically or cytologically confirmed diagnosis:
    • Nonrhabdomyosarcoma of soft tissue
    • Ewing sarcoma
    • Osteosarcoma at any site
  • Participant must be greater than 3 years of age and < 40 years of age.
  • Participant has not had any prior radiotherapy to the treatment site.
View Trial

TINI: Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL)

Diseases Treated:

Acute lymphoblastic leukemia (ALL)

Eligibility:

  • Newly diagnosed ALL
  • 1 year of age or younger at the time of diagnosis
  • Has not had any — or has had limited — prior therapy
  • Does not have mature B-cell ALL, acute myeloid leukemia (AML) or Down syndrome
View Trial